Before discussing brain- and lesion-targeted delivery approaches for remyelination therapeutic agents, we first present an overview of the beneficial roles of Fn at the BBB and detrimental roles of Fn in MS pathology and provide potential therapeutic agents to overcome Fn-mediated remyelination failure. The gene discussed is FN1; the disease is myeloid sarcoma.